Literature DB >> 1647195

Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNF alpha.

J P Sculier1, J J Body.   

Abstract

The rate of objective response to second-line chemotherapy with cyclophosphamide, adriamycin and vincristine increased from 13% to 55% in two consecutive series of patients with small-cell lung cancer when the therapy was potentiated by amphotericin B (2 mg/kg i.v.) entrapped in liposomes (= ampholiposomes). Patients who received ampholiposomes had a rapid and significant (p less than 0.01) increase of serum TNF alpha concentrations (median value: from less than 10 to 261 pg/mL) followed by a rise in serum neopterin and CRP. No major side effects were observed. Administration of ampholiposomes appeared to be a safe method for obtaining relatively high serum levels of TNF alpha that could potentiate anticancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647195     DOI: 10.1093/oxfordjournals.annonc.a057878

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  4 in total

1.  Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.

Authors:  M Larabi; P Legrand; M Appel; S Gil; M Lepoivre; J Devissaguet; F Puisieux; G Barratt
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Dramatic remission of nephrotic syndrome after unusual complication of mucormycosis in idiopathic membranous nephropathy.

Authors:  Wenling Ye; Yingyi Wang; Yubing Wen; Hang Li; Xuemei Li
Journal:  Int Urol Nephrol       Date:  2014-01-11       Impact factor: 2.370

3.  It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.

Authors:  Ana C Mesa-Arango; Liliana Scorzoni; Oscar Zaragoza
Journal:  Front Microbiol       Date:  2012-08-08       Impact factor: 5.640

4.  Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice.

Authors:  T Okutomi; T Ubukata; K Yamaoka; S Abe; H Yamaguchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.